Lecia V. Sequist on Side Effects From Agents for Resistant Lung Cancer

Lecia V. Sequist

Lecia V. Sequist, associate professor of medicine, Massachusetts General Hospital, discusses the adverse event profiles of rociletinib (CO-1686) and osimertinib (AZD9291), two agents specific to acquired T790M mutations in EGFR-positive non-small cell lung cancer (NSCLC).
Print | cure Printing...